TauRx Chairman to present at scientific symposium focused on advances in Alzheimer’s treatments

Mar 26 - 2014 05:00 AM
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s
Read more

TauRx Therapeutics to present at Social Care Conference in London on 25th March

Mar 23 - 2014 05:00 AM
TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future
Read more

Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an

Jan 09 - 2014 08:46 AM
Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen
Read more

First German patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease

Jan 08 - 2014 06:00 AM
Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Read more

TauRx Expands Alzheimer’s Clinical Trials in the United States

Jan 05 - 2014 06:00 AM
Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer’s disease
Read more